Effect of additional oral semaglutide vs sitagliptin on glycated haemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial
While lifestyle interventions are the cornerstone of obesity prevention and management, they often fail to result in sustained and meaningful weight loss (WL)
Not reporting side effects to the clinician
Fifth, previous CVOTs have suggested that the beneficial effects of GLP-1 RAs are primarily associated with long-acting agents such as liraglutide, semaglutide, and dulaglutide, rather than short-acting agents like exenatide and lixisenatide [17, 54, 56, 57, 68]
In contrast, when discussing tirzepatide vs retatrutide, it is notable that retatrutide is a novel triple agonist that activates GLP-1, GIP, and glucagon receptors